Cargando…
Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
The world is combating an ongoing COVID-19 pandemic with health-care systems, society and economies impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic. Therefore, reported COVID-19 cases do not refle...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665189/ https://www.ncbi.nlm.nih.gov/pubmed/33184284 http://dx.doi.org/10.1038/s41467-020-19481-7 |
_version_ | 1783609970357436416 |
---|---|
author | Slot, Ed Hogema, Boris M. Reusken, Chantal B. E. M. Reimerink, Johan H. Molier, Michel Karregat, Jan H. M. IJlst, Johan Novotný, Věra M. J. van Lier, René A. W. Zaaijer, Hans L. |
author_facet | Slot, Ed Hogema, Boris M. Reusken, Chantal B. E. M. Reimerink, Johan H. Molier, Michel Karregat, Jan H. M. IJlst, Johan Novotný, Věra M. J. van Lier, René A. W. Zaaijer, Hans L. |
author_sort | Slot, Ed |
collection | PubMed |
description | The world is combating an ongoing COVID-19 pandemic with health-care systems, society and economies impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic. Therefore, reported COVID-19 cases do not reflect the true scale of outbreak. Here we present the prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult population of the Netherlands, which is a highly affected country, using a high-performance immunoassay. Our results indicate that one month into the outbreak (i) the seroprevalence in the Netherlands was 2.7% with substantial regional variation, (ii) the hardest-hit areas showed a seroprevalence of up to 9.5%, (iii) the seroprevalence was sex-independent throughout age groups (18–72 years), and (iv) antibodies were significantly more often present in younger people (18–30 years). Our study provides vital information on the extent of exposure to SARS-CoV-2 in a country where social distancing is in place. |
format | Online Article Text |
id | pubmed-7665189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-76651892020-11-17 Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands Slot, Ed Hogema, Boris M. Reusken, Chantal B. E. M. Reimerink, Johan H. Molier, Michel Karregat, Jan H. M. IJlst, Johan Novotný, Věra M. J. van Lier, René A. W. Zaaijer, Hans L. Nat Commun Article The world is combating an ongoing COVID-19 pandemic with health-care systems, society and economies impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic. Therefore, reported COVID-19 cases do not reflect the true scale of outbreak. Here we present the prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult population of the Netherlands, which is a highly affected country, using a high-performance immunoassay. Our results indicate that one month into the outbreak (i) the seroprevalence in the Netherlands was 2.7% with substantial regional variation, (ii) the hardest-hit areas showed a seroprevalence of up to 9.5%, (iii) the seroprevalence was sex-independent throughout age groups (18–72 years), and (iv) antibodies were significantly more often present in younger people (18–30 years). Our study provides vital information on the extent of exposure to SARS-CoV-2 in a country where social distancing is in place. Nature Publishing Group UK 2020-11-12 /pmc/articles/PMC7665189/ /pubmed/33184284 http://dx.doi.org/10.1038/s41467-020-19481-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Slot, Ed Hogema, Boris M. Reusken, Chantal B. E. M. Reimerink, Johan H. Molier, Michel Karregat, Jan H. M. IJlst, Johan Novotný, Věra M. J. van Lier, René A. W. Zaaijer, Hans L. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands |
title | Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands |
title_full | Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands |
title_fullStr | Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands |
title_full_unstemmed | Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands |
title_short | Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands |
title_sort | low sars-cov-2 seroprevalence in blood donors in the early covid-19 epidemic in the netherlands |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665189/ https://www.ncbi.nlm.nih.gov/pubmed/33184284 http://dx.doi.org/10.1038/s41467-020-19481-7 |
work_keys_str_mv | AT sloted lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT hogemaborism lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT reuskenchantalbem lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT reimerinkjohanh lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT moliermichel lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT karregatjanhm lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT ijlstjohan lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT novotnyveramj lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT vanlierreneaw lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT zaaijerhansl lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands |